Flowerpot Table n / v prolong. 600mg 20 pieces

Description

Composition
Active substance:
1 tablet contains: 600 mg of pentoxifylline ;.
Excipients:
Hypromellose 15000 cP – 104.0 mg Microcrystalline cellulose – 13.5 mg crospovidone – 15.0 mg, colloidal silicon dioxide – 3.0 mg magnesium stearate – 4.5 mg; sheath: Macrogol 6000 – 3,943 mg talc – 11,842 mg Titanium dioxide – 3,943 mg, hypromellose 5 cP – 3.286 mg, polyacrylic acid (as a 30% dispersion) – 0.986 mg.
Description:
Oblong biconvex, film-coated white, scored on both sides. The core of white pills.
Product form:
Prolonged action tablets, film-coated, 600 mg.
10 tablets in PVC / Al blister. 2 blisters together with instructions for use in a cardboard box.
Contraindications
Hypersensitivity to pentoxifylline, other methylxanthine derivatives or other components forming part of the formulation;
Acute myocardial infarction;
Massive bleeding;
Retinal hemorrhage;
Acute hemorrhagic stroke;
Pregnancy;
Lactation;
Age 18 years (effectiveness and safety have been established).
Precautions: cerebral arteriosclerosis and / or coronary vessels, especially in cases of hypotension and cardiac arrhythmias; chronic heart failure, liver failure, renal failure (creatinine clearance less than 30 mL / min -. risk of accumulation and an increased risk of side effects), gastric ulcer and duodenal ulcers, has recently undergone surgical intervention (risk of bleeding), increased tendency to bleeding For example, when using anticoagulants, or in violation of blood coagulation (risk of more severe bleeding).
Dosage
600 mg
Indications
Violation of peripheral blood circulation against the background of atherosclerosis, diabetes, and inflammatory processes (including the “intermittent” claudication due to atherosclerosis, diabetic angiopathy, obliterative endarteritis);
Acute and chronic cerebrovascular accidents of ischemic origin;
Symptomatic treatment of the consequences of cerebrovascular atherosclerotic (impaired concentration, dizziness, memory impairment);
And atherosclerotic encephalopathy; angiopathy (paresthesia, Raynaud’s disease);
Trophic disorders of tissues due to violation of the arterial or venous microcirculation (trophic ulcers, post-trombophlebitic syndrome, chilblain, gangrene);
Circulatory disorders in the blood vessels of the eye (acute and chronic circulatory insufficiency in the network or in the choroid);
Dysfunction of middle ear vascular origin, accompanied by hearing loss.
Interaction with other drugs
Pentoxifylline may exacerbate the effects of drugs influencing blood coagulation (direct and indirect anticoagulants, thrombolytics), antibiotics (including cephalosporins – tsefamandola, cefoperazone, cefotetan), valproic acid. Increases effectiveness antihypertensives, insulin and hypoglycemic agents for oral administration.
Cimetidine increases the concentration of pentoxifylline in plasma (the risk of side effects).
Combined use with other xanthines can lead to excessive excitation of nerve.
In some patients, concomitant use of pentoxifylline and theophylline may lead to increased concentrations of theophylline (risk of side effects associated with theophylline).
Overdose
Symptoms: weakness, dizziness, tachycardia, drowsiness, marked reduction in blood pressure, redness of the skin, loss of consciousness, fever (chills), areflexia, tonic-clonic seizures, signs of gastrointestinal bleeding (vomiting-type “coffee grounds”).
Treatment: gastric lavage followed ingestion of activated carbon. In the case of vomiting with traces of blood gastric lavage is not allowed. Subsequently symptomatic treatment aimed at maintaining the respiratory function and blood pressure. In convulsions – diazepam.
pharmachologic effect
Pharmacological group:
Vasodilating agent.
Pharmacodynamics:
Xanthine derivative. Improves microcirculation in areas of impaired circulation. Improves blood rheology (flow) due to effects on pathologically altered erythrocyte deformability, elasticity increases the erythrocyte membrane and inhibits the aggregation of platelets and erythrocytes snizhaetpovyshennuyu blood viscosity. The mechanism of action is associated with inhibition of phosphodiesterase and the accumulation of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells and blood corpuscles elements. Pentoxifylline inhibits aggregation of red blood cells and platelets reduces the level of fibrinogen in plasma and enhances fibrinolysis, thus reducing blood viscosity and improves its flow characteristics. It improves oxygen supply to areas of impaired blood circulation, particularly in the limbs, the central nervous system, and to a lesser extent in the kidneys. When peripheral arterial occlusive disease ( “Intermittent” claudication) leads to an increase in walking distances eliminate nocturnal leg cramps, reduce pain at rest. In case of violation of cerebral circulation improves symptoms. Providing weak myotropic vasodilating action somewhat reduces the total peripheral vascular resistance and slightly dilates coronary vessels.
Pharmacokinetics:
After oral administration, pentoxifylline is almost completely absorbed from the gastrointestinal tract. Prolonged form provides sustained release and uniform absorption. Pentoxifylline is metabolized in the liver “first-pass”, thereby forming two pharmacologically active metabolite 1-5-hydroxyhexyl-3,7-dimethylxanthine (metabolite 1) and 1-3-carboxypropyl-3,7-dimethylxanthine (metabolite V ). Concentration of metabolite I and V, respectively, in the plasma 5 and 8 times higher than that of pentoxifylline. The ingestion of tablets Vazonita maximum concentration of pentoxifylline and its active metabolites in blood plasma is achieved after 3-4 h and stored at therapeutic levels for about 12 hours. The drug derived predominantly (94%) of the kidneys as metabolites. Excreted in breast milk. In severe renal dysfunction elimination of metabolites is slowed down. If abnormal liver function observed lengthening half-life, and increasing bioavailability.
Pregnancy and breast-feeding
Use of the drug during pregnancy and lactation is contraindicated.
Conditions of supply of pharmacies
On prescription.
side effects
Central nervous system: headache, dizziness, anxiety, sleep disorders, convulsions, cases of aseptic meningitis occur.
For the skin and subcutaneous fat: flushing of the face, “tides” of blood to the face skin and the upper part of the chest, swelling, increased fragility of the nails.
From the digestive system: dry mouth, feeling of pressure and fullness in the stomach, decreased appetite, nausea, vomiting, diarrhea, intestinal atony, aggravation cholecystitis, cholestatic hepatitis.
On the part of the organ of vision: blurred vision, scotoma.
Cardio-vascular system: tachycardia, arrhythmia, false angina, progressive angina, lower blood pressure.
From the side of hematopoiesis and hemostasis system: vredkih cases can cause bleeding (from the mucous membranes, skin, blood vessels, stomach, intestines), and thrombocytopenia, leukopenia, pancytopenia, gipofibrinogenemia, aplastic anemia. In this regard, the treatment of drug Vazonit® necessary to carry out regular monitoring of peripheral blood picture.
Allergic reactions: itching, skin flushing, urticaria, angioneurotic edema, anaphylactic shock.
Laboratory indicators: increase in activity of “liver” transaminases: alanine aminotransferase (ALT), aspartate aminotransferase (the ACT), and lactate dehydrogenase (LDH) and alkaline phosphatase.
special instructions
Patients with severe renal impairment at admission Vazonit® require especially careful medical supervision. If during the use of the drug in patients having bleeding in the retina of the eye, the drug overturned immediately.
Treatment should be under the control of blood pressure. Patients with low and unstable blood pressure dose administered must be reduced. Diabetic patients taking hypoglycemic agents, use can cause hypoglycemia in large doses (the dose required correction). In the application simultaneously with anticoagulants is necessary to monitor the performance of the blood coagulation system, including international normalized ratio (INR). In patients who have undergone recent surgery, a systematic monitoring of hemoglobin and hematocrit. Older people may need a dose reduction (increased bioavailability and reduced clearance rate). Smoking may reduce the therapeutic efficacy of the drug.
The effect on the ability of vehicles and machinery control
Due to the possible occurrence of dizziness caution is recommended when driving and maintenance of complex mechanisms. During the administration of the drug is not recommended the use of alcoholic beverages.
Storage conditions
In dry protected from light at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Vazonit® tablets should be taken orally without chewing, with enough liquid, preferably after the meal. The drug is usually administered 1 tablet of 600 mg 2 times a day (morning and evening), the maximum daily dose is 1200 mg. Duration of treatment and a drug dosing regimen Vazonit® set individually by the physician, depending on the clinical picture of the disease and the resulting therapeutic effect.
In patients with chronic renal failure (kreatnnina clearance less than 30 mL / min), the daily dose reduced to 600 mg.
Reducing the dose, taking into account the individual tolerance, it is necessary in patients with severely impaired hepatic function.
Treatment can be initiated with small doses in patients with low blood pressure, as well as in patients at risk due to a possible decrease in blood pressure (patients with severe ischemic heart disease or hemodynamically significant stenosis of the cerebral vessels). In these cases, the dose can be increased only gradually.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist